← Back to guidelines
Oncology26 papers

Cholangiocarcinoma of biliary tract

Last edited: 4/10/2026

Overview

Cholangiocarcinoma (CCA), a type of biliary tract cancer (BTC), is an aggressive and often fatal malignancy 1. Early symptom recognition, comprehensive diagnostic workup, and precise classification are crucial for effective management 1.

Diagnosis

  • Early recognition of symptoms and proper diagnostic workup are essential 1.
  • Diagnostic workup should allow for precise histopathological and molecular classification 1.
  • Accurate evaluation of the extent of disease is a key component of diagnosis 1.
  • Management

  • Surgery is the only potentially curative therapy for localized stages 1.
  • Adjuvant chemotherapy may improve survival following surgery 1.
  • Upfront systemic chemotherapy with immunotherapy is the treatment of choice for unresectable locally-advanced and metastatic disease 1.
  • New therapeutic targets are being identified based on understanding of molecular biology, showing encouraging results 1.
  • Key Recommendations

  • Surgery is the only potentially curative therapy in localized stages of biliary tract cancer 1. (Evidence: Expert opinion)
  • Adjuvant chemotherapy appears to improve survival in patients treated with surgery 1. (Evidence: Expert opinion)
  • Upfront systemic chemotherapy with immunotherapy is the treatment of choice for unresectable locally-advanced and metastatic disease 1. (Evidence: Expert opinion)
  • References

    1 Macarulla T, Adeva J, Cano Osuna MT, Ruiz Casado A, Jiménez Gordo AM, Lamarca A et al.. SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025. link

    Original source

    1. [1]
      SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025).Macarulla T, Adeva J, Cano Osuna MT, Ruiz Casado A, Jiménez Gordo AM, Lamarca A et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG